Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Wasif Saif

Showing results (471-480 of 473) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 473 results.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaHusain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.
Pageof 48

Showing results (471-480 of 473) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 473 results.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaHusain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.
Pageof 48